151
|
Forjaz de Lacerda G, Kelly SP, Bastos J, Castro C, Mayer A, Mariotto AB, Anderson WF. Breast cancer in Portugal: Temporal trends and age-specific incidence by geographic regions. Cancer Epidemiol 2018; 54:12-18. [PMID: 29544153 DOI: 10.1016/j.canep.2018.03.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Revised: 02/02/2018] [Accepted: 03/07/2018] [Indexed: 01/08/2023]
Abstract
BACKGROUND Female breast cancer incidence rates have been increasing in Portugal for years. We, therefore, conducted the first nationwide breast cancer study to assess regional differences. METHODS Cases were obtained from population-based cancer registries covering the country's Mainland (South, North, Centre), as well as the two Autonomous Regions (Azores and Madeira), for the time-period 1998 through 2011. Analyses were restricted to ages 30-84 years and stratified by region. We used the age-period-cohort (APC) framework to complement standard descriptive techniques and to forecast future trends. Estimable APC parameters included net drift, longitudinal age-specific incidence rate curves, and fitted age-specific incidence rate ratios. RESULTS There were 71 545 breast cancer cases diagnosed in Portugal at ages 30-84 years from 1998 to 2011. The South presented the highest age-standardized rate (155.8/100 000), while the North presented the fastest rate of increase (3.6%/year). Age-specific statistical interactions were observed between regions. Younger women in the North revealed a decreased risk of developing breast cancer compared to women from the same age group in the South and Centre, while that risk was reversed in older women (p < 0.05). We estimate that from 2014 onwards, the North might rank first among all regions. CONCLUSION The variant patterns observed could be due to a combination of different screening practices and/or exposure to risk factors across regions. Disease heterogeneity among younger and older women may also explain part of the differences in age-specific rates. These results justify continued monitoring of breast cancer incidence by region.
Collapse
Affiliation(s)
- Gonçalo Forjaz de Lacerda
- Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA; Azores Region Cancer Registry, Azores Oncological Centre, Portugal.
| | - Scott P Kelly
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Joana Bastos
- Centre Region Cancer Registry, Portuguese Institute of Oncology, Coimbra, Portugal
| | - Clara Castro
- Northern Region Cancer Registry, Portuguese Institute of Oncology, Porto, Portugal
| | - Alexandra Mayer
- Southern Region Cancer Registry, Portuguese Institute of Oncology, Lisbon, Portugal
| | - Angela B Mariotto
- Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA
| | - William F Anderson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| |
Collapse
|
152
|
Rosenberg P, Kjølhede P, Staf C, Bjurberg M, Borgfeldt C, Dahm-Kähler P, Hellman K, Hjerpe E, Holmberg E, Stålberg K, Tholander B, Åvall Lundqvist E, Högberg T. Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncol 2018; 57:346-353. [PMID: 28828920 DOI: 10.1080/0284186x.2017.1366048] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
AIM The aim of this study is to evaluate the quality of data on endometrial (EC) and ovarian, fallopian tube, peritoneal, abdominal or pelvic cancers (OC) registered in the Swedish Quality Register of Gynecologic Cancer (SQRGC). METHOD A random sample of 500 patients was identified in the SQRGC and their medical charts were reviewed for re-abstraction of 31 selected core variables by an independent validator. The data in the SQRGC and the re-abstracted data were compared. The data were collected from 25 hospitals evenly distributed throughout Sweden. The main outcomes were comparability, timeliness, completeness and validity. Coverage was compared with the National Cancer Register (NCR). Timeliness was defined as the speed of registration i.e. when patients were registered in the SQRGC relative to date of diagnosis. Internationally accepted coding systems for stage, grading and histologic type were used ensuring a high degree of comparability. Correlations were estimated using Pearson's correlation coefficient and Cohen´s kappa coefficient. RESULTS The completeness was 95%. The timeliness was 88-91% within 12 months of diagnosis. The median degree of agreement between re-abstracted data and data in the SQRGC was 82.1%, with a median kappa value of 0.73 for ordinate variables and a median Pearson's correlation coefficient of 0.96. The agreements for the type of surgery were 76% (95% CI 70-81%; kappa 0.49) and type of primary treatment 90% (95% CI 87-94%; kappa 0.85) in OC and in EC 88% (95% CI 84-93%; kappa 0.84). The agreements for the FIGO stage were in OC and EC 74% (95% CI 68-80%; kappa 0.69) and 87% (95% CI 82-91%; kappa 0.79), respectively. CONCLUSIONS The data in the Swedish Quality Register for Gynecologic Cancer are of adequate quality in order to be used as a basis for research and to evaluate possible differences in treatment, lead times and treatment results.
Collapse
Affiliation(s)
- Per Rosenberg
- Department of Oncology, Linköping University, Linköping, Sweden
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - Preben Kjølhede
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
- Department of Obstetrics and Gynecology, Linköping University, Linköping, Sweden
| | - Christian Staf
- Regional Cancer Center, Gothenburg, Sweden
- Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Maria Bjurberg
- Department of Clinical Sciences, Skåne University Hospital, Lund, Sweden
| | - Christer Borgfeldt
- Department of Obstetrics and Gynecology, Skåne University Hospital Lund University, Lund, Sweden
| | - Pernilla Dahm-Kähler
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
- Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg, Gothenburg, Sweden
| | - Kristina Hellman
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Elisabet Hjerpe
- Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Erik Holmberg
- Regional Cancer Center, Gothenburg, Sweden
- Sahlgrenska University Hospital, Gothenburg, Sweden
- Department of Oncology, Institute of Clinical Sciences Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Karin Stålberg
- Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden
| | | | - Elisabeth Åvall Lundqvist
- Department of Oncology, Linköping University, Linköping, Sweden
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - Thomas Högberg
- Department of Cancer Epidemiology, Lund University, Lund, Sweden
| |
Collapse
|
153
|
Stewart TS, Moodley J, Walter FM. Population risk factors for late-stage presentation of cervical cancer in sub-Saharan Africa. Cancer Epidemiol 2018; 53:81-92. [PMID: 29414636 DOI: 10.1016/j.canep.2018.01.014] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Revised: 01/18/2018] [Accepted: 01/22/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND Cervical cancer is the most prevalent malignancy in sub-Saharan Africa (SSA) with many women only seeking professional help when they are experiencing symptoms, implying late-stage malignancy and higher mortality rates. This ecological study assesses population-level exposures of SSA women to the numerous risk factors for HPV infection and cervical cancer, against late-stage presentation of cervical cancer. MATERIALS AND METHOD A literature review revealed the relevant risk factors in SSA. Open-access databases were mined for variables closely representing each risk factor. A proxy for late-stage presentation was used (ratio of incidence-to-mortality, IMR), and gathered from IARC's GLOBOCAN 2012 database. Variables showing significant correlation to the IMR were used in stepwise multiple regression to quantify their effect on the IMR. RESULTS Countries with high cervical cancer mortality rates relative to their incidence have an IMR nearer one, suggesting a larger proportion of late-stage presentation. Western Africa had the lowest median IMR (1.463), followed by Eastern Africa (IMR = 1.595) and Central Africa (IMR = 1.675), whereas Southern Africa had the highest median IMR (1.761). Variables selected for the final model explain 65.2% of changes seen in the IMR. Significant predictors of IMR were GDP (coefficient = 2.189 × 10-6, p = 0.064), HIV infection (-1.936 × 10-3, p = 0.095), not using a condom (-1.347 × 10-3, p = 0.013), high parity (-1.744 × 10-2, p = 0.008), and no formal education (-1.311 × 10-3, p < 0.001). CONCLUSION Using an IMR enables identification of factors predicting late-stage cervical cancer in SSA including: GDP, HIV infection, not using a condom, high parity and no formal education.
Collapse
Affiliation(s)
- Tessa S Stewart
- The University of Cambridge School of Clinical Medicine, Addenbrookes Hospital, Hills Road, Cambridge CB2 0SP, United Kingdom.
| | - Jennifer Moodley
- Women's Health Research Unit, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa; Cancer Research Initiative, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa; SAMRC Gynaecology Cancer Research Centre, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
| | - Fiona M Walter
- The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, United Kingdom.
| |
Collapse
|
154
|
Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, Park S, Hwang JS. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol 2018; 33:475-483. [PMID: 28612951 DOI: 10.1111/jgh.13848] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Revised: 05/16/2017] [Accepted: 06/08/2017] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND AIM Over the past decade, the management of hepatocellular carcinoma (HCC) and viral hepatitis has been improved. We explored survival trends and factors affecting survival of HCC in a hepatitis B virus (HBV)-endemic population. METHODS From 31 521 and 38 167 HCC registrants to the population-based national cancer registry in Korea, an HBV-endemic country, in the period of 2003-2005 and 2008-2010, we randomly sampled cohorts of 4515 and 4582 patients, respectively, for the investigation of clinical characteristics and survival. RESULTS Compared with Cohort 2003-2005, Cohort 2008-2010 had significantly better liver function (Child-Turcotte-Pugh class A, 64.2% vs 71.6%; P < 0.001) and had more advanced tumor stages (Barcelona Clinic Liver Cancer stage B-D, 45.8% vs 50.4%; P < 0.001). HBV was the predominant cause of HCC in both cohorts (62.5% vs 62.2%; P = 0.70). Cohort 2008-2010 had significantly better overall survival than Cohort 2003-2005 by age-adjusted univariate, multivariable, and propensity score-matched analyses (median survival time, 17.2 vs 28.4 months; P < 0.001). In a subcohort analysis, a consistently significant inter-cohort improvement in survival was observed only in patients with HBV-related HCC (median survival, 16.1 vs 30.4 months; P < 0.001). The annual number of patients with HCC receiving oral antiviral agents for HBV precipitously increased from 93 in 2005 to 28 520 in 2010 in the country. CONCLUSIONS The consistent improvement in survival of patients with HCC was confined to HBV-related HCC subcohort over the last decade in an HBV-endemic population. The survival improvement coincided with the exponential use of oral antiviral agents for HBV in the patients.
Collapse
Affiliation(s)
- Bo Hyun Kim
- Center for Liver Cancer, National Cancer Center, Goyang, Republic of Korea.,Korean Liver Cancer Association, Seoul, Republic of Korea
| | - Young-Suk Lim
- Korean Liver Cancer Association, Seoul, Republic of Korea.,Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
| | - Eun-Yang Kim
- Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Republic of Korea
| | - Hyun-Joo Kong
- Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Republic of Korea
| | - Young-Joo Won
- Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Republic of Korea
| | - Seungbong Han
- Department of Applied Statistics, Gachon University, Seongnam, Republic of Korea
| | - Sohee Park
- Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea
| | - Jae Seok Hwang
- Korean Liver Cancer Association, Seoul, Republic of Korea.,Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea
| |
Collapse
|
155
|
Stenning-Persivale K, Franco MJS, Cordero-Morales A, Cruzado-Burga J, Poquioma E, Nava ED, Payet E. The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima. Ecancermedicalscience 2018; 12:799. [PMID: 29456616 PMCID: PMC5813917 DOI: 10.3332/ecancer.2018.799] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Indexed: 12/29/2022] Open
Abstract
Introduction The Mortality–Incidence Ratio complement [1 – MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima. Materials and methods The Metropolitan Lima Cancer Registry (RCLM in Spanish) for 2004–2005 was used to determine the number of new cases and the number of deaths of the following cancers: breast, stomach, prostate, thyroid, lung, colon, cervical, and liver cancers, as well as non-Hodgkin’s lymphoma and leukaemia. To determine the five-year survival, the five-year vital status of cases recorded was verified in the National Registry of Identification and Civil Status (RENIEC in Spanish). A linear regression model was used to assess the correlation between [1 – MIR] and total observed five-year survival for the selected cancers. Results Observed and estimated five-year survival determined by [1 – MIR] for each neoplasia were thyroid (66.7%, 86.7%), breast (69.6%; 68%), prostate (64.3%, 63.8%) and cervical (50.1%, 58.5%), respectively. Pearson’s r coefficient for the correlation between [MIR – 1] and observed survival was = 0.9839. Using the coefficient of determination, it was found that [1 – MIR] (X) captures the 96.82% of observed survival (Y). Conclusion The Mortality–Incidence Ratio complement [1 – MIR] is an appropriate tool for approximating observed five-year survival for the ten types of cancers studied. This study demonstrates the validity of this model for predicting five-year survival in cancer patients in metropolitan Lima.
Collapse
|
156
|
Darre T, Kpatcha TM, Bagny A, Maneh N, Gnandi-Piou F, Tchangai B, Daré S, Adani-Ifé S, Walla A, Amégbor K, Napo-Koura G. Descriptive Epidemiology of Cancers in Togo from 2009 to 2016. Asian Pac J Cancer Prev 2017; 18:3407-3411. [PMID: 29286611 PMCID: PMC5980902 DOI: 10.22034/apjcp.2017.18.12.3407] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Background: Cancer is a global public health problem. According to World Report on Cancer in 2000, developing
countries are becoming increasingly affected. Methods: This retrospective and descriptive 8-year study of all histological
confirmed cancers was conducted using data from the anatomical pathology laboratory registry of Togo’s only laboratory.
The parameters were frequency, site and histological type as well as age and gender. Results: We found 1,738 cancers in
patients aged from 4 months to 109 years (mean, 50.4 ± 4. The sex ratio (M/F) was 1.3. The most frequent localizations
of the cancers were the prostate (10.3%) followed by the breast (9.9%), the stomach (8.4%) and the cervix (7.2%). In
women, the median age was 47.4 ± 2.9 years, and the most common cancers were breast cancer (21.2%), followed
by cervical cancer (16.3%). In men, the median age was 53.2 ± 7.3 years and the most frequent cancers were prostate
cancer (18.5%), non-Hodgkin’s lymphoma (13.2%) and stomach cancer (10.7%). In children, Burkitt’s lymphoma
(41.8%), retinoblastoma (11.6%) and nephroblastoma (9.6%) were the most important cancers. Conclusion: Cancers
are frequent in Togo, those of the prostate, breast and cervix being most important with a worse prognosis. Emphasis
should be placed on early detection and diagnosis.
Collapse
Affiliation(s)
- Tchin Darre
- Department of Pathology, University Teaching Hospital of Lomé, Lomé, Togo. Email :
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
157
|
Merriel SWD, Turner EL, Walsh E, Young GJ, Metcalfe C, Hounsome L, Tudge I, Donovan J, Hamdy F, Neal D, Martin RM. Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). BMJ Open 2017; 7:e015994. [PMID: 29138196 PMCID: PMC5695381 DOI: 10.1136/bmjopen-2017-015994] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Accepted: 06/07/2017] [Indexed: 12/29/2022] Open
Abstract
OBJECTIVES To compare the completeness and agreement of prostate cancer data recorded by the National Cancer Registration and Analysis Service (NCRAS) with research-level data specifically abstracted from medical records from the Cluster randomised triAl of prostate specific antigen (PSA) testing for Prostate cancer (CAP) trial. DESIGN Cross-sectional comparison study. PARTICIPANTS We included 1356 men from the CAP trial cohort who were linked to the NCRAS registry. PRIMARY AND SECONDARY OUTCOME MEASURES Completeness of prostate cancer data in NCRAS and CAP and agreement for tumour, node, metastases (TNM) stage (T1/T2; T3; T4/N1/M1) and Gleason grade (4-6; 7; 8-10), measured by differences in proportions and Cohen's kappa statistic. Data were also stratified by year and pre-2010 versus post-2010, when NCRAS reporting standards changed. RESULTS Compared with CAP, completeness was lower in NCRAS for Gleason grade (41.2% vs 76.7%, difference 35.5, 95% CI 32.1 to 39.0) and TNM stage (29.9% vs 67.6%, difference 37.6, 95% CI 34.1 to 41.1). NCRAS completeness for Gleason grade (pre-2010 vs post-2010 31.69% vs 64%; difference 32.31, 95% CI 26.76 to 37.87) and TNM stage (19.31% vs 55.50%; difference 36.19, 95% CI 30.72 to 41.67) improved over time. Agreement for Gleason grade was high (Cohen's kappa, κ=0.90, 95% CI 0.88 to 0.93), but lower for TNM stage (κ=0.41, 95% CI 0.37 to 0.51) overall. There was a trend towards improved agreement on Gleason grade, but not TNM stage, when comparing pre-2010 and post-2010 data. CONCLUSION NCRAS case identification was very high; however, data on prostate cancer grade was less complete than CAP, and agreement for TNM stage was modest. Although the completeness of NCRAS data has improved since 2010, the higher completeness rate in CAP demonstrates that gains could potentially be achieved in routine registry data. This study's findings highlight a need for improved recording of stage and grade data in the source medical records.
Collapse
Affiliation(s)
| | - Emma L Turner
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Eleanor Walsh
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Grace J Young
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Chris Metcalfe
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Luke Hounsome
- Public Health England National Cancer Registration and Analysis Service, Bristol, UK
| | - Isobel Tudge
- Public Health England National Cancer Registration and Analysis Service, Bristol, UK
| | - Jenny Donovan
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Freddie Hamdy
- Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK
| | - David Neal
- Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK
| | - Richard M Martin
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| |
Collapse
|
158
|
Piñeros M, Ramos W, Antoni S, Abriata G, Medina LE, Miranda JJ, Payet E, Bray F. Cancer patterns, trends, and transitions in Peru: a regional perspective. Lancet Oncol 2017; 18:e573-e586. [PMID: 28971824 DOI: 10.1016/s1470-2045(17)30377-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 03/10/2017] [Accepted: 03/22/2017] [Indexed: 01/24/2023]
Abstract
Peru, like several other South American countries, is experiencing remarkable population growth, ageing, and urbanisation, which has given rise to profound changes in its epidemiological profile. Prostate and breast cancer are the most frequent cancers in men and women, respectively, in Lima and Arequipa, the two areas with population-based cancer registries. However, infection-associated cancers (cervix and stomach) are also common, and rank highest in the national cancer mortality profile. Although a foundation of surveillance informs cancer-control initiatives in Peru, improvements in the vital statistics system, and the quality and use of incidence data for the planning and assessment of cancer prevention and control actions, are needed. Existing population-based cancer registries in Lima and Arequipa, and linkages to the established national mandatory cancer reporting system, are crucial for the collection of high-quality data on national cancer incidence. The delivery of effective cancer prevention and control measures requires sustained investment in the collection of high-quality data capable of informing policies and driving research programmes.
Collapse
Affiliation(s)
- Marion Piñeros
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
| | - Willy Ramos
- National Centre of Disease Epidemiology, Prevention and Control, Ministry of Health, Peru
| | - Sébastien Antoni
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | | | - Luis E Medina
- Population-based Cancer Registry of Arequipa, Instituto Regional de Enfermedades Neoplásicas del Sur, Arequipa, Peru
| | - J Jaime Miranda
- CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru; School of Medicine, University Cayetano Heredia, Lima, Peru
| | - Eduardo Payet
- Metropolitan Lima Cancer Registry, National Institute of Neoplastic Diseases, Lima, Peru
| | - Freddie Bray
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
159
|
Incidence of Cancer in Shenzhen, Guangdong Province during 2001-2015: A Retrospective Population-Based Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2017; 14:ijerph14101137. [PMID: 28953262 PMCID: PMC5664638 DOI: 10.3390/ijerph14101137] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 09/22/2017] [Accepted: 09/22/2017] [Indexed: 02/07/2023]
Abstract
Cancer is a serious public health issue and the leading cause of death around the world. This article aimed to estimate the cancer incidence and the trend in standardized cancer incidence in Shenzhen, Guangdong province, South China during 2001–2015 by analyzing the cancer data of the population-based cancer registry in Shenzhen. Data were collected from the cancer registry in Shenzhen, which was conducted during 2001–2015. In this registry, the crude incidence rates, age-specific incidence rates, age-standardized incidence rates and cumulative incidence rates were calculated in every five years. Trends for standardized incidence rates of cancers were analyzed by using the joinpoint regression analysis. In total, 33,374.3 thousand person-years (17,593.9 thousand for males and 15,780.4 thousand for females) were monitored over this time period. The number of new cancer cases during 2001–2015 was 59,218 (30,144 and 29,074 for males and females, respectively). The crude incidence during 2001–2005 was 136.44 per 100,000 persons, while the age-standardized rates by Chinese standard population (ASR-China) and by world standard population (ASR-world) were 165.13 and 212.48 per 100,000 persons, respectively. The crude incidence during 2006–2010 was 179.01 per 100,000 persons, while the ASR-China and ASR-world were 168.08 and 214.44 per 100,000 persons, respectively. The crude incidence during 2011–2015 was 196.53 per 100,000 persons, while the ASR-China and ASR-world were 171.44 and 219.99 per 100,000 persons, respectively. During 2001 and 2015, the joinpoint regression analysis showed that the ASR-China of cancer had an overall increase of 0.96% per year and 0.84% per year for males and females respectively, although both of these values (males and females) were non-significant increases. The leading cancer types during 2011–2015 were lung, colorectal, thyroid gland, breast, liver, stomach, cervix, nasopharynx, leukemia and lymphoma. For males, the top five common cancers were lung, liver, colorectal, stomach and thyroid gland. For females, the top five common cancers were breast, thyroid gland, lung, colorectal and cervix. The results of this study showed a heavy cancer burden among the population of Shenzhen, China. Future researches of the etiology and prevention of cancers should be planned in order to reduce the incidence associated with cancers in the future.
Collapse
|
160
|
The impact of under-reporting of cases on the estimates of childhood cancer incidence and survival in Estonia. Eur J Cancer Prev 2017; 26 Joining forces for better cancer registration in Europe:S147-S152. [DOI: 10.1097/cej.0000000000000377] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
161
|
Evaluation of completeness of case ascertainment in Swiss cancer registration. Eur J Cancer Prev 2017; 26 Joining forces for better cancer registration in Europe:S139-S146. [DOI: 10.1097/cej.0000000000000380] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
162
|
Hille J, Johnson NW. The burden of oral cancer in sub-Saharan Africa. TRANSLATIONAL RESEARCH IN ORAL ONCOLOGY 2017. [DOI: 10.1177/2057178x17721094] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Jos Hille
- Department of Oral and Maxillofacial Pathology, University of the Western Cape, and National Health Laboratories, Tygerberg Laboratories, Cape Town, South Africa
| | - Newell W Johnson
- Menzies Health Institute Queensland and School of Dentistry and Oral Health, Griffith University, Gold Coast Campus, Queensland, Australia
| |
Collapse
|
163
|
Donnelly C, Cairnduff V, Chen JJ, Kearney T, Fitzpatrick D, Fox C, Gavin A. The completeness and timeliness of cancer registration and the implications for measuring cancer burden. Cancer Epidemiol 2017; 49:101-107. [PMID: 28600946 DOI: 10.1016/j.canep.2017.05.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 04/13/2017] [Accepted: 05/12/2017] [Indexed: 01/20/2023]
Abstract
BACKGROUND Population based cancer registration provides a critical role in disease surveillance in terms of incidence, survival, cancer cluster investigations and prevalence trends, and therefore high levels of completeness and timeliness are required. This study estimates completeness and variation between early and late registrations in the N. Ireland Cancer Registry (NICR) and assesses the implications for reporting cancer incidence and for registry-based research. METHODS Two main approaches assessed completeness. For the period 2010-2012, incidence reported in the first year of data publication was compared to incidence reported in subsequent years until 2015. Demographic characteristics and survival of incident cases ascertained before the first publication year were compared to those ascertained in subsequent years. The flow method approach was used to estimate completeness annually after the incident year. RESULTS Overall incidence for all cancers increased between the first year of data publication and subsequent years up to 2015, irrespective of year of diagnosis. Late registrations had poorer survival. The flow method approach estimated the completeness of case ascertainment of NICR data to be 96% complete at five years for all cancers combined. CONCLUSION The estimated completeness levels for the NICR are comparable to other high quality cancer registries internationally. While data timeliness has little impact on incidence estimates, delays in registration may have implications for specific research studies into incidence and survival. This means that improvements in the timeliness of reporting should be a target for all registries but not at the expense of completeness.
Collapse
Affiliation(s)
- Conan Donnelly
- Northern Ireland Cancer Registry, Queens University Belfast,Mulhouse Building, Grosvenor Road, BT12 6DP, UK.
| | - Victoria Cairnduff
- Northern Ireland Cancer Registry, Queens University Belfast,Mulhouse Building, Grosvenor Road, BT12 6DP, UK
| | | | - Therese Kearney
- Northern Ireland Cancer Registry, Queens University Belfast,Mulhouse Building, Grosvenor Road, BT12 6DP, UK
| | - Deirdre Fitzpatrick
- Northern Ireland Cancer Registry, Queens University Belfast,Mulhouse Building, Grosvenor Road, BT12 6DP, UK
| | - Colin Fox
- Northern Ireland Cancer Registry, Queens University Belfast,Mulhouse Building, Grosvenor Road, BT12 6DP, UK
| | - Anna Gavin
- Northern Ireland Cancer Registry, Queens University Belfast,Mulhouse Building, Grosvenor Road, BT12 6DP, UK
| |
Collapse
|
164
|
High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer. Transplantation 2017; 101:1295-1302. [DOI: 10.1097/tp.0000000000001225] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
165
|
Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J. Cancer incidence and mortality in China, 2013. Cancer Lett 2017; 401:63-71. [PMID: 28476483 DOI: 10.1016/j.canlet.2017.04.024] [Citation(s) in RCA: 312] [Impact Index Per Article: 44.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Revised: 04/11/2017] [Accepted: 04/14/2017] [Indexed: 12/14/2022]
Abstract
OBJECTIVE National Central Cancer Registry of China (NCCRC) updated nationwide statistics of cancer incidence and mortality in China using population-based cancer registration data in 2013 from all available cancer registries. METHODS In 2016, 255 registries' data were qualified and included in this analysis. We estimated numbers of new cancer cases and deaths in China in 2013 using age-specific rates and corresponding national population stratified by area, sex, age group (0, 1-4, 5-9, 10-14…85+) and cancer type. The world Segi's population was applied for age-standardized rates. All rates were expressed per 100,000 person-year. RESULTS A total of 3,682,000 new cancer cases and 2,229,300 cancer deaths were estimated in China in 2013. Cancers of lung, female breast, stomach, liver, colon-rectum and esophagus were the most common cancers, accounting for about half of all cancer new cases. Lung cancer, liver cancer, stomach cancer, esophageal cancer, colorectal cancer were the five leading causes of cancer death, accounting for about 60% of all cancer deaths. The cancer patterns showed differences not only between male and female, but also among different geographic regions in China. For overall cancers, the age-standardized incidence rates were stable during the past decades in male, but significantly increased by 2.2% per year in female. CONCLUSIONS Cancer poses a major threat to public health and the cancer burden keep raising in China. The annual updated cancer statistics can provide scientific basis for cancer prevention and control.
Collapse
Affiliation(s)
- Wanqing Chen
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| | - Rongshou Zheng
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Siwei Zhang
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Hongmei Zeng
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Changfa Xia
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Tingting Zuo
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Zhixun Yang
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Xiaonong Zou
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Jie He
- National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| |
Collapse
|
166
|
Liu H, Lin G, Li K, Ding H, Xu H, Li Y, Dong H, Song S. Evolution of Cancer Registration Combining Online Reporting with Follow-up in the Community: Practices in Guangzhou, China. Asian Pac J Cancer Prev 2017; 18:639-646. [PMID: 28440969 PMCID: PMC5464478 DOI: 10.22034/apjcp.2017.18.3.639] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Background: An efficient registration system with accurate and timely information on cancer incidence and mortality is key to development of policies to prevent and control cancer. A traditional registration system usually needs 3-4 years to collect data and publish a cancer report. However, researchers, policymakers and healthcare professionals need to know the latest cancer registration data quickly. Methods: A computer system has been operating with cases reported online by hospitals and followed up in communities at the Cancer Registry of Guangzhou (CRG) since 2008. The comparability, completeness, accuracy and timeliness of collected data were here evaluated. Results: From 2010 to 2014, 181,194 cancer cases from 1,916,253 medical records of cancer were reported to the CRG online. 53,473 cases were deleted as duplicates (47,906), wrong diagnoses (410) or residents of other places (5,157) during the follow up. Successful final follow-up rates were over 90% for both newly and previously diagnosed cases by general practitioners in community clinics. The CRG coding and classification system follows international standards. The annual trends for all sites by sex were stable from 2010 to 2014. All age-specific incidence rates for childhood cancers were within the limits of the respective international references. The overall M: I ratio for all sites but C44 was 56.7%., ratios for most sites in Guangzhou being between Hong Kong and Shanghai. A total of 75.7% of the cancer cases reported in 2010–2012 were morphologically verified. Ninety five percent of new cases completed registration within 29.0 months in 2010, reducing to 8.0 months in 2014. Conclusion: The online report system with community follow up at the CRG yields reasonably accurate and close-to-complete data. It takes less time to confirm diagnosis and other information so that reporting annual incidence one year after the close of registration becomes possible.
Collapse
Affiliation(s)
- Huazhang Liu
- Cancer Registry, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
| | | | | | | | | | | | | | | |
Collapse
|
167
|
Leinonen MK, Miettinen J, Heikkinen S, Pitkäniemi J, Malila N. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer 2017; 77:31-39. [DOI: 10.1016/j.ejca.2017.02.017] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Revised: 02/19/2017] [Accepted: 02/21/2017] [Indexed: 10/19/2022]
|
168
|
Fiessler C, Pfahlberg AB, Keller AK, Radespiel-Tröger M, Uter W, Gefeller O. Association between month of birth and melanoma risk: fact or fiction? Int J Epidemiol 2017; 46:686-693. [PMID: 27649803 DOI: 10.1093/ije/dyw226] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/20/2016] [Indexed: 12/29/2022] Open
Abstract
Background Evidence on the effect of ultraviolet radiation (UVR) exposure in infancy on melanoma risk in later life is scarce. Three recent studies suggest that people born in spring carry a higher melanoma risk. Our study aimed at verifying whether such a seasonal pattern of melanoma risk actually exists. Methods Data from the population-based Cancer Registry Bavaria (CRB) on the birth months of 28 374 incident melanoma cases between 2002 and 2012 were analysed and compared with data from the Bavarian State Office for Statistics and Data Processing on the birth month distribution in the Bavarian population. Crude and adjusted analyses using negative binomial regression models were performed in the total study group and supplemented by several subgroup analyses. Results In the crude analysis, the birth months March-May were over-represented among melanoma cases. Negative binomial regression models adjusted only for sex and birth year revealed a seasonal association between melanoma risk and birth month with 13-21% higher relative incidence rates for March, April and May compared with the reference December. However, after additionally adjusting for the birth month distribution of the Bavarian population, these risk estimates decreased markedly and no association with the birth month was observed any more. Similar results emerged in all subgroup analyses. Conclusions Our large registry-based study provides no evidence that people born in spring carry a higher risk for developing melanoma in later life and thus lends no support to the hypothesis of higher UVR susceptibility during the first months of life.
Collapse
Affiliation(s)
- Cornelia Fiessler
- Department of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany and
| | - Annette B Pfahlberg
- Department of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany and
| | - Andrea K Keller
- Department of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany and
| | - Martin Radespiel-Tröger
- Bavarian Health and Food Safety Authority, Centre for Early Cancer Detection and Cancer Registration, Nuremberg, Germany
| | - Wolfgang Uter
- Department of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany and
| | - Olaf Gefeller
- Department of Medical Informatics, Biometry and Epidemiology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany and
| |
Collapse
|
169
|
Piñeros M, Abriata MG, Mery L, Bray F. Cancer registration for cancer control in Latin America: a status and progress report. Rev Panam Salud Publica 2017; 41:e2. [PMID: 31391813 PMCID: PMC6660887 DOI: 10.26633/rpsp.2017.2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 12/21/2015] [Indexed: 12/30/2022] Open
Abstract
Cancer incidence by type has been included as a core indicator in the World Health Organization (WHO) Global Monitoring Framework for the Prevention and Control of Noncommunicable Diseases. The Global Initiative for Cancer Registry Development (GICR), coordinated by the International Agency for Research on Cancer (IARC), supports low- and middle-income countries to reduce disparities in cancer information for cancer control by increasing the coverage and quality of cancer registration. A baseline assessment has been performed at the IARC Regional Hub for Latin America using secondary and public information sources. Countries have been categorized according to the following criteria for population-based cancer registries (PBCRs): 1) "has no established PBCR (but some registration activity)," 2) "has established PBCR(s) but none of high-quality," and 3) "has established, high-quality PBCR(s) (regional or national)." Currently, in LatinAmerica, most countries have cancer control plans in place; PBCRs cover approximately20% of the region's population, though only 7% are deemed as having high-quality information. No information is available on the extent of use of the information generated by PBCRs for cancer control purposes. Though there are important advances in cancer registration in the region, there is still much to be done. This report also outlines key elementsfor improving cancer surveillance in the region, including 1) involvement of local stakeholders and experts, 2) integration of cancer registries into existing surveillance systems(accounting for the complexities and particularities of cancer surveillance), 3) improvementin data availability and quality, 4) enhanced communication and dissemination, and 5) better linkages between cancer registries and cancer planning and cancer research.
Collapse
Affiliation(s)
- Marion Piñeros
- Cancer Surveillance SectionInternational Agency for Research on CancerLyonFrance
| | | | - Les Mery
- Cancer Surveillance SectionInternational Agency for Research on CancerLyonFrance
| | - Freddie Bray
- Cancer Surveillance SectionInternational Agency for Research on CancerLyonFrance
| |
Collapse
|
170
|
Choi E, Lee S, Nhung BC, Suh M, Park B, Jun JK, Choi KS. Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries. Epidemiol Health 2017; 39:e2017006. [PMID: 28171715 PMCID: PMC5434228 DOI: 10.4178/epih.e2017006] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 02/05/2017] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVES Assessing long-term success and efficiency is an essential part of evaluating cancer control programs. The mortality-to-incidence ratio (MIR) can serve as an insightful indicator of cancer management outcomes for individual nations. By calculating MIRs for the top five cancers in Organization for Economic Cooperation and Development (OECD) countries, the current study attempted to characterize the outcomes of national cancer management policies according to the health system ranking of each country. METHODS The MIRs for the five most burdensome cancers globally (lung, colorectal, prostate, stomach, and breast) were calculated for all 34 OECD countries using 2012 GLOBOCAN incidence and mortality statistics. Health system rankings reported by the World Health Organization in 2000 were updated with relevant information when possible. A linear regression model was created, using MIRs as the dependent variable and health system rankings as the independent variable. RESULTS The linear relationships between MIRs and health system rankings for the five cancers were significant, with coefficients of determination ranging from 49 to 75% when outliers were excluded. A clear outlier, Korea reported lower-than-predicted MIRs for stomach and colorectal cancer, reflecting its strong national cancer control policies, especially cancer screening. CONCLUSIONS The MIR was found to be a practical measure for evaluating the long-term success of cancer surveillance and the efficacy of cancer control programs, especially cancer screening. Extending the use of MIRs to evaluate other cancers may also prove useful.
Collapse
Affiliation(s)
- Eunji Choi
- Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
| | - Sangeun Lee
- Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
| | - Bui Cam Nhung
- Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
| | - Mina Suh
- National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Boyoung Park
- Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.,National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Jae Kwan Jun
- Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.,National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Kui Son Choi
- Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.,National Cancer Control Institute, National Cancer Center, Goyang, Korea
| |
Collapse
|
171
|
Abstract
In the field of rare diseases, registries are considered power tool to develop clinical research, to facilitate the planning of appropriate clinical trials, to improve patient care and healthcare planning. Therefore high quality data of rare diseases registries is considered to be one of the most important element in the establishment and maintenance of a registry. Data quality can be defined as the totality of features and characteristics of data set that bear on its ability to satisfy the needs that result from the intended use of the data. In the context of registries, the 'product' is data, and quality refers to data quality, meaning that the data coming into the registry have been validated, and ready for use for analysis and research. Determining the quality of data is possible through data assessment against a number of dimensions: completeness, validity; coherence and comparability; accessibility; usefulness; timeliness; prevention of duplicate records. Many others factors may influence the quality of a registry: development of standardized Case Report Form and security/safety controls of informatics infrastructure. With the growing number of rare diseases registries being established, there is a need to develop a quality validation process to evaluate the quality of each registry. A clear description of the registry is the first step when assessing data quality or the registry evaluation system. Here we report a template as a guide for helping registry owners to describe their registry.
Collapse
|
172
|
Zhao J, Zuo T, Zheng R, Zhang S, Zeng H, Xia C, Yang Z, Chen W. Epidemiology and trend analysis on malignant mesothelioma in China. Chin J Cancer Res 2017; 29:361-368. [PMID: 28947868 PMCID: PMC5592824 DOI: 10.21147/j.issn.1000-9604.2017.04.09] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Objective Population-based cancer registration data were used to analyze the epidemiology and trend of malignant mesothelioma in China, and the result would provide basic data for its prevention and control. Methods Malignant mesothelioma data in 2013 were retrieved from the database of National Cancer Registry. Malignant mesothelioma incidence and mortality were estimated using age-specific rate by urban/rural and gender according to the national population in 2013. Malignant mesothelioma data from 22 cancer registries were used for trend analysis during 2000–2013. Results It is estimated that there were 2,041 new malignant mesothelioma cases and 1,659 malignant mesothelioma deaths occurred in 2013. The crude incidence rate in China were 1.50/106 (males 1.67/106, females 1.32/106), age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 1.03/106 and 1.02/106, respectively. The crude mortality rate in China was 1.22/106 (males 1.67/106, females 1.32/106), age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 0.83/106 and 0.81/106, respectively. There was an increasing trend of incidence rate for malignant mesothelioma in registration areas of China during 2000–2013 with annual percentage change (APC) of 2.5% [95% confidence interval (95% CI): 0.6%–4.5%]. After age standardization, no significant differences were observed. No matter for crude mortality rates or age-standardized mortality rates, no significant differences were observed during 2000–2013.
Conclusions Malignant mesothelioma is the major occupational and environmental neoplasm associated with asbestos exposure. The increasing incidence trend suggests that more attention should be paid on this disease.
Collapse
Affiliation(s)
- Jun Zhao
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Tingting Zuo
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Rongshou Zheng
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Siwei Zhang
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Hongmei Zeng
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Changfa Xia
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Zhixun Yang
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Wanqing Chen
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
173
|
Crocetti E, Randi G. Using the Benford's Law as a First Step to Assess the Quality of the Cancer Registry Data. Front Public Health 2016; 4:225. [PMID: 27790609 PMCID: PMC5061771 DOI: 10.3389/fpubh.2016.00225] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 09/28/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Benford's law states that the distribution of the first digit different from 0 [first significant digit (FSD)] in many collections of numbers is not uniform. The aim of this study is to evaluate whether population-based cancer incidence rates follow Benford's law, and if this can be used in their data quality check process. METHODS We sampled 43 population-based cancer registry populations (CRPs) from the Cancer Incidence in 5 Continents-volume X (CI5-X). The distribution of cancer incidence rate FSD was evaluated overall, by sex, and by CRP. Several statistics, including Pearson's coefficient of correlation and distance measures, were applied to check the adherence to the Benford's law. RESULTS In the whole dataset (146,590 incidence rates) and for each sex (70,722 male and 75,868 female incidence rates), the FSD distributions were Benford-like. The coefficient of correlation between observed and expected FSD distributions was extremely high (0.999), and the distance measures low. Considering single CRP (from 933 to 7,222 incidence rates), the results were in agreement with the Benford's law, and only a few CRPs showed possible discrepancies from it. CONCLUSION This study demonstrated for the first time that cancer incidence rates follow Benford's law. This characteristic can be used as a new, simple, and objective tool in data quality evaluation. The analyzed data had been already checked for publication in CI5-X. Therefore, their quality was expected to be good. In fact, only for a few CRPs several statistics were consistent with possible violations.
Collapse
Affiliation(s)
- Emanuele Crocetti
- Health in Society Unit, Directorate F Health, Consumers and Reference Materials, Joint Research Centre (JRC), European Commission , Ispra , Italy
| | - Giorgia Randi
- Health in Society Unit, Directorate F Health, Consumers and Reference Materials, Joint Research Centre (JRC), European Commission , Ispra , Italy
| |
Collapse
|
174
|
Sierra MS, Forman D. Cancer in Central and South America: Methodology. Cancer Epidemiol 2016; 44 Suppl 1:S11-S22. [PMID: 27678312 DOI: 10.1016/j.canep.2016.07.020] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Revised: 07/04/2016] [Accepted: 07/31/2016] [Indexed: 11/20/2022]
Abstract
Statistics on cancer incidence from Central and South American countries are scarce because of the small number of population-based cancer registries that continuously collect data. Similarly, comparable statistics on cancer mortality are sparse in spite of efforts made to improve coverage in the last decade. The aim of this study is to describe geographical patterns and trends in cancer incidence and mortality in Central and South America in the 21st century. The primary objective was to obtain the best quality cancer data available from each country within the region. Cancer incidence data were obtained from population-based cancer registries within the region and, in countries where these did not exist, from hospital-based registries; national mortality data were obtained from the World Health Organization mortality database. Given the variability in data quality - mainly due to the age and development in maturity of the registries, an exhaustive review of the data was necessary in order to appropriately analyze, describe and interpret patterns of cancer incidence and mortality between countries and within cancer-specific sites. This paper presents the methods employed in the collection, quality control and analysis of the datasets received for the project.
Collapse
Affiliation(s)
- Mónica S Sierra
- International Agency for Research on Cancer, Section of Cancer Surveillance, France.
| | - David Forman
- International Agency for Research on Cancer, Section of Cancer Surveillance, France
| |
Collapse
|
175
|
Sierra MS, Soerjomataram I, Forman D. Prostate cancer burden in Central and South America. Cancer Epidemiol 2016; 44 Suppl 1:S131-S140. [PMID: 27678315 DOI: 10.1016/j.canep.2016.06.010] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Revised: 05/24/2016] [Accepted: 06/27/2016] [Indexed: 01/01/2023]
Abstract
RATIONALE AND OBJECTIVE The incidence of prostate cancer has increased in Central and South America (CSA) in the last few decades. We describe the geographical patterns and trends of prostate cancer in CSA. METHODS We obtained regional and national-level cancer incidence data from 48 population-based registries in 13 countries and nation-wide cancer deaths from the WHO mortality database for 18 countries. We estimated world population age-standardized incidence (ASR) and mortality (ASMR) rates per 100,000 person-years for 2003-2007 and the estimated annual percent change (EAPC) to describe time trends. RESULTS Prostate cancer was the most common cancer diagnosis and one of the leading causes of cancer deaths among males in most CSA countries. From 2003-2007, ASRs varied between countries (6-fold) and within countries (Brazil: 3-6-fold). French Guyana (147.1) and Brazil (91.4) had the highest ASRs whereas Mexico (28.9) and Cuba (24.3) had the lowest. ASMRs varied by 4-fold. Belize, Uruguay and Cuba (24.1-28.9) had the highest ASMRs while Peru, Nicaragua, and El Salvador (6.8-9.7) had the lowest. In Argentina, Brazil, Chile and Costa Rica prostate cancer incidence increased by 2.8-4.8% annually whereas mortality remained stable between 1997 and 2008. CONCLUSION The geographic and temporal variation of prostate cancer rates observed in CSA may in part reflect differences in diagnostic and registration practices, healthcare access, treatment and death certification, and public awareness. The incidence of prostate cancer is expected to increase given recent early detection activities and increased public awareness; however, the impact of these factors on mortality remains to be elucidated.
Collapse
Affiliation(s)
- Mónica S Sierra
- International Agency for Research on Cancer, Section of Cancer Surveillance, France.
| | | | - David Forman
- International Agency for Research on Cancer, Section of Cancer Surveillance, France
| |
Collapse
|
176
|
Perdomo S, Martin Roa G, Brennan P, Forman D, Sierra MS. Head and neck cancer burden and preventive measures in Central and South America. Cancer Epidemiol 2016; 44 Suppl 1:S43-S52. [PMID: 27678322 DOI: 10.1016/j.canep.2016.03.012] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Revised: 03/14/2016] [Accepted: 03/21/2016] [Indexed: 01/01/2023]
Abstract
RATIONALE AND OBJECTIVE Central and South America comprise one of the areas characterized by high incidence rates for head and neck cancer. We describe the geographical and temporal trends in incidence and mortality of head and neck cancers in the Central and South American region in order to identify opportunities for intervention on the major identified risk factors: tobacco control, alcohol use and viral infections. METHODS We obtained regional- and national-level incidence data from 48 population-based cancer registries in 13 countries and cancer deaths from the WHO mortality database for 18 countries. Age-standardized incidence (ASR) and mortality (ASMR) rates per 100,000 person-years were estimated. RESULTS Brazil had the highest incidence rates for oral and pharyngeal cancer in the region for both sexes, followed by Cuba, Uruguay and Argentina. Cuba had the highest incidence and mortality rates of laryngeal cancer in the region for males and females. Overall, males had rates about four times higher than those in females. Most countries in the region have implemented WHO recommendations for both tobacco and alcohol public policy control. CONCLUSION Head and neck squamous-cell cancer (HNSCC) incidence and mortality rates in the Central and South America region vary considerably across countries, with Brazil, Cuba, French Guyana, Uruguay and Argentina experiencing the highest rates in the region. Males carry most of the HNSCC burden. Improvement and implementation of comprehensive tobacco and alcohol control policies as well as the monitoring of these factors are fundamental to prevention of head and neck cancers in the region.
Collapse
Affiliation(s)
- Sandra Perdomo
- International Agency for Research on Cancer, Section of Genetics, France.
| | | | - Paul Brennan
- International Agency for Research on Cancer, Section of Genetics, France
| | - David Forman
- International Agency for Research on Cancer, Section of Cancer Surveillance, France
| | - Mónica S Sierra
- International Agency for Research on Cancer, Section of Cancer Surveillance, France
| |
Collapse
|
177
|
Izarzugaza MI, Fernández L, Forman D, Sierra MS. Burden of gallbladder cancer in Central and South America. Cancer Epidemiol 2016; 44 Suppl 1:S82-S89. [PMID: 27678326 DOI: 10.1016/j.canep.2016.07.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 07/26/2016] [Accepted: 07/31/2016] [Indexed: 02/07/2023]
Abstract
RATIONALE AND OBJECTIVE Gallbladder carcinoma (GBC) is a rare neoplasm yet it is the most common malignancy of the biliary tract and its prognosis is poor. Incidence of GBC is high in some areas of Central and South America and the Caribbean. We described the current burden of GBC in Central and South America (CSA). METHODS We obtained GBC incidence data from 48 population-based cancer registries in 13 countries in CSA, and national level cancer death data from the WHO mortality data base for 18 countries. We estimated World population age-standardized incidence and mortality rates per 100,000 persons-years, including distribution and incidence rates by anatomic subsite. RESULTS GBC rates were the highest in countries located in the Andean region. In 2003-2007, Chile had the highest incidence and mortality rates in CSA (17.1 and 12.9 in females and 7.3 and 6.0 in males, respectively). Females had higher GBC rates than males. The most frequently diagnosed anatomic subsite was gallbladder (60%). Unspecified subsite represented 21% of all cases. Trends in incidence and mortality of GBC remained unchanged in Argentina, Brazil, Chile and Costa Rica in 1998-2008. CONCLUSION GBC rates varied extensively across the CSA region reflecting, in part, differences in data quality, coverage and healthcare access. Chile had the highest GBC rates in CSA and the world. The large proportion of unspecified cases indicates low precision in diagnosis/registration and highlights the need to promote and improve cancer registration in the region to better understand the burden of GBC in CSA.
Collapse
Affiliation(s)
| | - Leticia Fernández
- National School of Public Health of Cuba, Biostatistics Department, Cuba
| | - David Forman
- The International Agency for Research on Cancer, Cancer Surveillance Section, Lyon, France
| | - Mónica S Sierra
- The International Agency for Research on Cancer, Cancer Surveillance Section, Lyon, France.
| |
Collapse
|
178
|
Meng R, Wei K, Xia L, Xu Y, Chen W, Zheng R, Lin L. Cancer incidence and mortality in Guangdong province, 2012. Chin J Cancer Res 2016; 28:311-20. [PMID: 27478316 PMCID: PMC4949276 DOI: 10.21147/j.issn.1000-9604.2016.03.05] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Objective To estimate the cancer incidence and mortality in 2012 in Guangdong province by analyzing the cancer data of selected population-based cancer registries in Guangdong province in 2012. Methods Eight of nine population-based cancer registries submitted cancer data to the Guangdong Provincial Centre for Disease Control and Prevention (Guangdong CDC), whose data met the data quality criteria were included for analysis. The statistics of selected registries, stratified by areas, gender, age and cancer types, were used to estimate the cancer incidence and mortality in 2012 in Guangdong province according to the population data in Guangdong province. Segi’s population and the national census population in 2000 were used for calculating the age-standardized rates (ASR). Results A total of 15,084,942 people, accounted for 17.47% of all population in Guangdong province, were covered in 8 selected population-based cancer registries in 2012. The percentage of cases morphologically verified (MV%) and the percentage of death certificate-only cases (DCO%) were 72.84% and 0.87%, respectively, and the mortality/incidence (M/I) ratio was 0.56. It was estimated that there were 211,300 new cancer cases and 117,300 cancer deaths. The incidence crude rate (CR), the ASR by Chinese standard population (ASRC) and by world standard population (ASRW), and the accumulated rate (AR) (0.74 years)
were 250.20/100,000 (265.39/100,000 in males, 234.29/100,000 in females), 207.04/100,000, 201.34/100,000 and 22.91%, respectively, in Guangdong province in 2012. The incidence CR and ASRC were 267.25/100,000 and 221.43/100,000 in urban areas, and 215.51/100,000 and 178.77/100,000 in rural areas, respectively. The death CR, ASRC, ASRW and AR (0.74 years) were 148.44/100,000 (190.95/100,000 in males, 105.06/100,000 in females), 103.73/100,000, 102.44/100,000 and 11.68%, respectively, in Guangdong province in 2012. The death CR and ASRC were 164.57/100,000 and 105.46/100,000 in urban areas, and 124.63/100,000 and 99.97/100,000 in rural areas, respectively. Top 5 cancers were lung cancer, liver cancer, female breast cancer, colon cancer and nasopharyngeal cancers (NPC), and top 5 death cancers were lung cancer, liver cancer, colon cancer, stomach cancer, and NPC in Guangdong province in 2012. Conclusions Lung cancer, liver cancer, female breast cancer, colon cancer and NPC were the major economic cancer burdens and health concerns in Guangdong province in 2012. Early prevention, diagnosis and treatment of different cancers, survival quality improvement and cancer burden reduction, are important issues we faced in cancer control and prevention.
Collapse
Affiliation(s)
- Ruilin Meng
- Institute of Control and Prevention for Chronic Non-infective Disease, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
| | - Kuangrong Wei
- Institute of Cancer, Zhongshan People's Hospital, Zhongshan 528403, China
| | - Liang Xia
- Institute of Control and Prevention for Chronic Non-infective Disease, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
| | - Yanjun Xu
- Institute of Control and Prevention for Chronic Non-infective Disease, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
| | - Wanqing Chen
- Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College & National Cancer Center, Beijing 100021, China
| | - Rongshou Zheng
- Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College & National Cancer Center, Beijing 100021, China
| | - Lifeng Lin
- Institute of Control and Prevention for Chronic Non-infective Disease, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
| |
Collapse
|
179
|
Validation of data quality in the Swedish National Register for Oesophageal and Gastric Cancer. Br J Surg 2016; 103:1326-35. [DOI: 10.1002/bjs.10234] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 02/15/2016] [Accepted: 05/17/2016] [Indexed: 01/08/2023]
Abstract
Abstract
Background
The Swedish National Register for Oesophageal and Gastric Cancer (NREV) was launched in 2006. Data are reported at diagnosis (diagnostic survey), at the time of surgery (surgical survey) and at first outpatient follow-up (follow-up survey). The aim of this study was to evaluate data originating from NREV in terms of comparability, completeness, accuracy and timeliness.
Methods
Coding routines were compared with international standards and completeness was evaluated by means of a 5-year (2009–2013) comparison with mandatory national registers. Validity was tested by comparison with reabstracted data from source medical records in 400 patients chosen randomly with stratification for hospital size and catchment area population. Timeliness of registration was described.
Results
Coding routines followed national and international guidelines. Compared with the Swedish Cancer Registry from 2009 to 2013, 6069 (95·5 per cent) of 6354 patients were registered in NREV at the time of data extraction. Of 60 variables investigated, 10 966 of 12 035 original entries were correct in the reabstraction, resulting in an exact agreement of 91·1 per cent in the register. There were 782 (6·5 per cent) incorrect and 287 (2·4 per cent) missing entries. Median time to registration was 3·9, 3·4 and 4·1 months for diagnostic, surgical and follow-up surveys respectively.
Conclusion
NREV has reached a position with good coverage of those with the relevant diagnoses, and contains comparable and valid data. Quality data on each variable are available. Timeliness is an area with potential for improvement.
Collapse
|
180
|
Kee KM, Wang JH, Wang CC, Cheng YF, Lu SN. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival. Sci Rep 2016; 6:30156. [PMID: 27444261 PMCID: PMC4957107 DOI: 10.1038/srep30156] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 06/29/2016] [Indexed: 12/17/2022] Open
Abstract
Clinical manifestations between hepatocellular carcinoma (HCC) and extra-hepatic primary malignancy (EHPM) are lack of large-scale study. We enrolled 14555 HCC patients between 1986 and 2013 retrospectively. The EHPM was classified as prior, synchronous and metachronous group based on before, within and after 6 months of HCC diagnosis, respectively. The incidence rate of EHPM is 3.91% (95% confidence interval [CI]: 3.60–4.23%). Urogenital cancers, kidney and bladder, were at unexpected higher ranks. Older in age, Child-Pugh A cirrhosis, negativity of HBsAg and anti-HCV, and earlier BCLC staging are independent factors associated with EHPM. The survival rates of EHPM improve over time and also better than HCC-alone. Cox proportional-hazards regression shows independent poor prognostic factors are age >60, male, AFP levels ≥400 ng/ml, positivity of HBsAg, Child-Pugh B vs. A, Non-metachronous group, respectively, treated with local ablation, transcatheter arterial embolization, radiotherapy and supportive care vs. surgery, respectively, TNM stage IIIA vs. I, and BCLC stages A, B, C and D vs. 0, respectively. Survival of EHPM improve could be explained by early diagnosis and improve treatment of cancers.
Collapse
Affiliation(s)
- Kwong Ming Kee
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Jing-Houng Wang
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Chih-Chi Wang
- Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Yu-Fan Cheng
- Department of Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Sheng-Nan Lu
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| |
Collapse
|
181
|
Valberg M, Grotmol T, Tretli S, Veierød MB, Moger TA, Devesa SS, Aalen OO. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals? Eur J Epidemiol 2016; 32:511-520. [PMID: 27431530 DOI: 10.1007/s10654-016-0185-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 07/09/2016] [Indexed: 11/24/2022]
Abstract
After the introduction of the prostate specific antigen (PSA) test in the 1980s, a sharp increase in the incidence rate of prostate cancer was seen in the United States. The age-specific incidence patterns exhibited remarkable shifts to younger ages, and declining rates were observed at old ages. Similar trends were seen in Norway. We investigate whether these features could, in combination with PSA testing, be explained by a varying degree of susceptibility to prostate cancer in the populations. We analyzed incidence data from the United States' Surveillance, Epidemiology, and End Results program for 1973-2010, comprising 511,027 prostate cancers in men ≥40 years old, and Norwegian national incidence data for 1953-2011, comprising 113,837 prostate cancers in men ≥50 years old. We developed a frailty model where only a proportion of the population could develop prostate cancer, and where the increased risk of diagnosis due to the massive use of PSA testing was modelled by encompassing this heterogeneity in risk. The frailty model fits the observed data well, and captures the changing age-specific incidence patterns across birth cohorts. The susceptible proportion of men is [Formula: see text] in the United States and [Formula: see text] in Norway. Cumulative incidence rates at old age are unchanged across birth cohort exposed to PSA testing at younger and younger ages. The peaking cohort-specific age-incidence curves of prostate cancer may be explained by the underlying heterogeneity in prostate cancer risk. The introduction of the PSA test has led to a larger number of diagnosed men. However, no more cases are being diagnosed in total in birth cohorts exposed to the PSA era at younger and younger ages, even though they are diagnosed at younger ages. Together with the earlier peak in the age-incidence curves for younger cohorts, and the strong familial association of the cancer, this constitutes convincing evidence that the PSA test has led to a higher proportion, and an earlier timing, of diagnoses in a limited pool of susceptible individuals.
Collapse
Affiliation(s)
- Morten Valberg
- Department of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
| | - Tom Grotmol
- Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
| | - Steinar Tretli
- Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
| | - Marit B Veierød
- Department of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Tron A Moger
- Department of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
- Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway
| | - Susan S Devesa
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Odd O Aalen
- Department of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| |
Collapse
|
182
|
Khodadost M, Yavari P, Khodadost B, Babaei M, Sarvi F, Khatibi SR, Barzegari S. Estimating the Esophagus Cancer Incidence Rate in Ardabil, Iran: A Capture-Recapture Method. IRANIAN JOURNAL OF CANCER PREVENTION 2016; 9:e3972. [PMID: 27413513 PMCID: PMC4934015 DOI: 10.17795/ijcp-3972] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 09/22/2015] [Indexed: 11/25/2022]
Abstract
Background: Accurate cancer registry and awareness of cancer incidence rate is essential in order to define strategies for cancer prevention and control programs. Capture-recapture methods have been recommended for reducing bias and increase the accuracy of cancer incidence estimation. Objectives: This study aimed to estimate the esophagus cancer incidence by capture-recapture method based on Ardabil population-based cancer registry data. Patients and Methods: Total new cases of esophagus cancer reported by three sources of pathology reports, medical records, and death certificates to Ardabil province cancer registry center in 2006 and 2008 were enrolled in the study. All duplicated cases between three sources were identified and removed using Excel software. Some characteristics such as name, surname, father’s name, date of birth and ICD codes related to their cancer type were used for data linkage and finding the common cases among three sources. The incidence rate per 100,000 was estimated based on capture-recapture method using the log-linear models. We used BIC, G2 and AIC statistics to select the best-fit model. Results: After removing duplicates, total 471 new cases of esophagus cancer were reported from three sources. The model with linkage between pathology reports, medical record sources and independence with the death certificates source was the best fitted model. The reported incidence rate for the years 2006 and 2008 was 18.77 and 18.51 per 100,000, respectively. In log-linear analysis, the estimated incidence rate for the years 2006 and 2008 was 49.71 and 53.87 per 100,000 populations, respectively. Conclusions: Based on the obtained results, it can be concluded that none of the sources of pathology reports, death certificates and medical records individually or collectively were fully covered the incidence cases of esophagus cancer and need to apply some changes in data abstracting and case finding.
Collapse
Affiliation(s)
- Mahmoud Khodadost
- Gastroenterology and Liver Diseases Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran; Department of Epidemiology, Faculty of Health, Iran University of Medical Sciences, Tehran, IR Iran
| | - Parvin Yavari
- Department of Health and Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran , IR Iran
| | - Behnam Khodadost
- Department of Epidemiology, Faculty of Health, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Masoud Babaei
- Health Deputy, Ardabil University of Medical sciences, Ardabil, IR Iran; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Fatemeh Sarvi
- Epidemiology and Biostatistics Department, School of Public Health, Hamadan University of Medical Sciences, Hamadan, IR Iran
| | - Seyed Reza Khatibi
- Department of Epidemiology, Faculty of Health, Iran University of Medical Sciences, Tehran, IR Iran
| | - Saeed Barzegari
- Department of Health Information Technology, Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, IR Iran
| |
Collapse
|
183
|
Fung JWM, Lim SBL, Zheng H, Ho WYT, Lee BG, Chow KY, Lee HP. Data quality at the Singapore Cancer Registry: An overview of comparability, completeness, validity and timeliness. Cancer Epidemiol 2016; 43:76-86. [PMID: 27399312 DOI: 10.1016/j.canep.2016.06.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Revised: 06/21/2016] [Accepted: 06/23/2016] [Indexed: 10/21/2022]
Abstract
AIM To provide a comprehensive evaluation of the quality of the data at the Singapore Cancer Registry (SCR). METHODS Quantitative and semi-quantitative methods were used to assess the comparability, completeness, accuracy and timeliness of data for the period of 1968-2013, with focus on the period 2008-2012. RESULTS The SCR coding and classification systems follow international standards. The overall completeness was estimated at 98.1% using the flow method and 97.5% using the capture-recapture method, for the period of 2008-2012. For the same period, 91.9% of the cases were morphologically verified (site-specific range: 40.4-100%) with 1.1% DCO cases. The under-reporting in 2011 and 2012 due to timely publication was estimated at 0.03% and 0.51% respectively. CONCLUSION This review shows that the processes in place at the SCR yields data which are internationally comparable, relatively complete, valid, and timely, allowing for greater confidence in the use of quality data in the areas of cancer prevention, treatment and control.
Collapse
Affiliation(s)
- Janice Wing Mei Fung
- National Registry of Diseases Office, Singapore Cancer Registry, Health Promotion Board, 3 Second Hospital Avenue, Singapore 168937, Singapore.
| | - Sandra Bee Lay Lim
- National Registry of Diseases Office, Singapore Cancer Registry, Health Promotion Board, 3 Second Hospital Avenue, Singapore 168937, Singapore
| | - Huili Zheng
- National Registry of Diseases Office, Singapore Cancer Registry, Health Promotion Board, 3 Second Hospital Avenue, Singapore 168937, Singapore
| | - William Ying Tat Ho
- National Registry of Diseases Office, Singapore Cancer Registry, Health Promotion Board, 3 Second Hospital Avenue, Singapore 168937, Singapore
| | - Bee Guat Lee
- National Registry of Diseases Office, Singapore Cancer Registry, Health Promotion Board, 3 Second Hospital Avenue, Singapore 168937, Singapore
| | - Khuan Yew Chow
- National Registry of Diseases Office, Singapore Cancer Registry, Health Promotion Board, 3 Second Hospital Avenue, Singapore 168937, Singapore
| | - Hin Peng Lee
- Saw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive 2 #10-01 Singapore 117549, Singapore
| |
Collapse
|
184
|
Can breast cancer register data on recommended adjuvant treatment be used as a proxy for actually given treatment? Eur J Oncol Nurs 2016; 22:1-7. [DOI: 10.1016/j.ejon.2016.02.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 02/10/2016] [Accepted: 02/11/2016] [Indexed: 11/19/2022]
|
185
|
Leinonen MK, Rantanen M, Pitkäniemi J, Malila N. Coverage and accuracy of myeloproliferative and myelodysplastic neoplasms in the Finnish Cancer Registry. Acta Oncol 2016; 55:782-6. [PMID: 26767306 DOI: 10.3109/0284186x.2015.1127416] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Background Registration of haematological malignancies presents specific challenges, and a wide range of data is required to ensure case ascertainment and proper classification of these diseases. We studied the data quality of myeloproliferative and myelodysplastic neoplasms in the Finnish Cancer Registry (FCR), comparing information with hospital discharges. Material and methods Hospital discharges (HILMO) in 2007-2013 including diagnostic codes of myeloproliferative and myelodysplastic neoplasms were extracted. Patients were individually linked to the FCR database for all haematological malignancies registered in 1953-2013. Coverage and accuracy of the FCR and agreement between registers was estimated. Results In total 5289 individuals were retrieved from two registers. Of these, 1406 were common, 1080 only found in the FCR and 2803 only in the HILMO. Coverage of myeloproliferative and myelodysplastic neoplasms in the FCR was 47.0% (95% CI 45.7-48.4%). Almost one quarter of the registrations in the FCR was based on a death certificate only. The accuracy of diagnosis was 51.4% (95% CI 49.4-53.3%), but it varied substantially by disease category. Kappa statistic for agreement between registers was excellent (0.83, 95% CI 0.80-0.85) for common cases. 7.6% of cases in the HILMO was registered as leukaemias in the FCR. Conclusions More than half of the patients found in the HILMO were entirely missing from the FCR. However, some of the diagnoses in HILMO may be preliminary and this represents the maximal number of missing cases. Cancer registers benefit from supplementary data sources, such as hospital discharges, to increase coverage and accuracy of register data on haematological malignancies.
Collapse
Affiliation(s)
- Maarit K Leinonen
- Cancer Society of Finland, Finnish Cancer Registry, Helsinki, Finland
| | - Matti Rantanen
- Cancer Society of Finland, Finnish Cancer Registry, Helsinki, Finland
| | - Janne Pitkäniemi
- Cancer Society of Finland, Finnish Cancer Registry, Helsinki, Finland
| | - Nea Malila
- Cancer Society of Finland, Finnish Cancer Registry, Helsinki, Finland
| |
Collapse
|
186
|
Sun X, Han S, Gu F, Lin G, Wang Z, Wang Y, Xu Y. A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma. J Cancer 2016; 7:1066-73. [PMID: 27326249 PMCID: PMC4911873 DOI: 10.7150/jca.13547] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 03/15/2016] [Indexed: 01/29/2023] Open
Abstract
Purpose: To retrospectively compare taxane-based with fluorouracil-based chemoradiotherapy in terms of toxicity profiles, efficacy and survival in patients with inoperable esophageal cancer. Methods and Materials: We analyzed retrospectively 179 consecutive patients who were unresectable or medically unfit for surgery between March 2009 and November 2014. Eight-three patients were included in the taxane group and 96 cases were in the fluorouracil group. Results: The overall response rate (ORR) in the taxane group was higher than fluorouracil group, but was not significantly different (71.6% vs. 63.5%, respectively, P=0.255). In total, 53.0% (44/83) of the patients in the taxane group had progressive disease versus 54.2% (52/96) in the fluorouracil group (not significantly different (P=0.758)). There was no significant difference in overall response rate, progression free survival and overall survival, as well as treatment-related death. In terms of non-hematological toxicity, patients in the taxane group experienced a lower incidence of ≥ grade 3 esophageal perforation or fistula (4.8% vs. 13.5%, P=0.047) and pneumonia (4.8% vs. 9.7%, P=0.242). Regarding hematological toxicity, thrombocytopenia in the taxane group was significantly lower (4.8% vs. 13.5%, P=0.047), but there was a trend towards a higher rate of ≥ grade 3 leukopenia (34.9% vs.26.0%, P=0.196). Conclusions: Chemoradiation with taxane-based regimens is well tolerated, with potentially promising efficacy, and could become a good alternative treatment in a first line setting for patients with inoperable esophageal squamous cell carcinoma.
Collapse
Affiliation(s)
- Xiaojiang Sun
- 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China
| | - Shuiyun Han
- 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China
| | - Feiying Gu
- 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China
| | - Gang Lin
- 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China
| | - Zhun Wang
- 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China
| | - Yuezhen Wang
- 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China
| | - Yaping Xu
- 1. Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou China;; 2. Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China
| |
Collapse
|
187
|
Ekanem IOA, Parkin DM. Five year cancer incidence in Calabar, Nigeria (2009-2013). Cancer Epidemiol 2016; 42:167-72. [PMID: 27164305 DOI: 10.1016/j.canep.2016.04.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 04/05/2016] [Accepted: 04/23/2016] [Indexed: 01/10/2023]
Abstract
Cancer incidence rates are presented for the Calabar Cancer Registry, a population-based cancer registry (PBCR) covering the population of two Local Government Areas (LGAs) of Calabar the capital of Cross-River State, Nigeria. (375,196 inhabitants in 2006). During the period 2009-2013, a total of 719 new cases were registered comprising 320 men (an age standardised incidence rate (ASR) of 78.8 per 100,000) and 399 women (ASR of 86.9 per 100,000). Breast and cervical cancers account for 60.4% of all cancers in women, with breast cancer (ASR 35 per 100,000) almost twice as common as cervix cancer (ASR 21 per 100,000) and occurring in rather younger women. Prostate cancer was the most common cancer in men (ASR 50.8 per 100,000). Hodgkin's lymphoma was common in both sexes, and there were moderate numbers of HIV-related cancers recorded (Kaposi sarcoma, non Hodgkin lymphoma, and squamous cell carcinomas of conjunctiva).
Collapse
Affiliation(s)
- Ima-Obong A Ekanem
- Calabar Cancer Registry, Department of Pathology, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria.
| | - Donald M Parkin
- Nuffield Department of Population Health, University of Oxford, OX3 7LF, UK.
| |
Collapse
|
188
|
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Jonas J, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castañeda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Tillman T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M. The Global Burden of Cancer 2013. JAMA Oncol 2016; 1:505-27. [PMID: 26181261 DOI: 10.1001/jamaoncol.2015.0735] [Citation(s) in RCA: 1969] [Impact Index Per Article: 246.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
IMPORTANCE Cancer is among the leading causes of death worldwide. Current estimates of cancer burden in individual countries and regions are necessary to inform local cancer control strategies. OBJECTIVE To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 28 cancers in 188 countries by sex from 1990 to 2013. EVIDENCE REVIEW The general methodology of the Global Burden of Disease (GBD) 2013 study was used. Cancer registries were the source for cancer incidence data as well as mortality incidence (MI) ratios. Sources for cause of death data include vital registration system data, verbal autopsy studies, and other sources. The MI ratios were used to transform incidence data to mortality estimates and cause of death estimates to incidence estimates. Cancer prevalence was estimated using MI ratios as surrogates for survival data; YLDs were calculated by multiplying prevalence estimates with disability weights, which were derived from population-based surveys; YLLs were computed by multiplying the number of estimated cancer deaths at each age with a reference life expectancy; and DALYs were calculated as the sum of YLDs and YLLs. FINDINGS In 2013 there were 14.9 million incident cancer cases, 8.2 million deaths, and 196.3 million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million) for men and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer was the leading cause for cancer death in men and women, with 1.6 million deaths. For men, TBL cancer was the leading cause of DALYs (24.9 million). For women, breast cancer was the leading cause of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000 and age-standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in developing vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver cancer (ASIR, 15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical cancer (ASIR, 8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by more than 10% in 113 countries and decreased by more than 10% in 12 of 188 countries. CONCLUSIONS AND RELEVANCE Cancer poses a major threat to public health worldwide, and incidence rates have increased in most countries since 1990. The trend is a particular threat to developing nations with health systems that are ill-equipped to deal with complex and expensive cancer treatments. The annual update on the Global Burden of Cancer will provide all stakeholders with timely estimates to guide policy efforts in cancer prevention, screening, treatment, and palliation.
Collapse
Affiliation(s)
| | - Christina Fitzmaurice
- Division of Hematology, Department of Medicine, University of Washington, Seattle2Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Daniel Dicker
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Amanda Pain
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Hannah Hamavid
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Maziar Moradi-Lakeh
- Institute for Health Metrics and Evaluation, University of Washington, Seattle3Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Michael F MacIntyre
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Christine Allen
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Gillian Hansen
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Rachel Woodbrook
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | | | | | | | - Andrea Werdecker
- Institute of Medical Sociology and Social Medicine, Marburg, Germany
| | | | - Braden Te Ao
- Department of Biostatistics and Epidemiology, School of Public Health and Psychosocial Studies, Auckland University of Technology, Auckland, New Zealand
| | - Brian McMahon
- Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
| | - Chante Karimkhani
- College of Physicians and Surgeons, Columbia University, New York, New York
| | - Chuanhua Yu
- Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, China
| | | | - David C Schwebel
- Department of Psychology, University of Alabama at Birmingham, Birmingham, Alabama
| | - David O Carpenter
- Institute for Health and the Environment, University at Albany, Rensselaer, New York
| | - David M Pereira
- Laboratório de Farmacognosia, Departamento de Ciências Químicas, Faculdade de Farmácia, University do Porto, REQUIMTE/LAQV, Porto, Portugal
| | - Denis Nash
- School of Public Health, Hunter College Campus, City University of New York, New York
| | | | | | - Dietrich Plass
- Federal Environment Agency Section on Exposure Assessment and Environmental Health Indicators, Berlin, Germany
| | - Kingsley N Ukwaja
- Department of Internal Medicine, Federal Teaching Hospital, Abakaliki, Nigeria
| | - George D Thurston
- Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York
| | - Kim Yun Jin
- Faculty of Chinese Medicine, Southern University College, Johor, Malaysia
| | - Edgar P Simard
- Rollins School of Public Health, Emory University, Atlanta, Georgia
| | | | - Eun-Kee Park
- Department of Medical Humanities and Social Medicine, Kosin University College of Medicine, Busan, South Korea
| | - Ferrán Catalá-López
- Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Ministry of Health, Madrid, Spain
| | | | - Carolyn Gotay
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - Gulfaraz Khan
- Department of Microbiology & Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
| | | | - Itamar S Santos
- Centre for Clinical and Epidemiological Research, University of São Paulo, São Paulo, Brazil
| | | | - Jasvinder Singh
- Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama
| | | | - Jost B Jonas
- Department of Ophthalmology, University of Heidelberg, Mannheim, Germany
| | | | - Juan Sanabria
- Department of Surgery, Case Western Reserve University, Cleveland, Ohio38Nutrition and Preventive Medicine, Chicago Medical School at Cancer Treatment Centers of America, Rosalind Franklin University, Chicago, Illinois
| | - Justin Beardsley
- Nuffield Department of Medicine, Oxford University, Ho Chi Minh City, Vietnam
| | - Kathryn H Jacobsen
- Department of Global and Community Health, George Mason University, Fairfax, Virginia
| | - Ken Takahashi
- Department of Environmental Epidemiology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Richard C Franklin
- College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Australia
| | - Luca Ronfani
- Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy
| | - Marcella Montico
- Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy
| | - Luigi Naldi
- Azienda Ospedaliera papa Giovanni XXIII, Bergamo, Italy
| | | | - Johanna Geleijnse
- Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands
| | - Max Petzold
- Centre for Applied Biostatistics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden48School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
| | | | | | | | | | - Paul Yip
- The University of Hong Kong, Hong Kong, China
| | - Farshad Pourmalek
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Paulo A Lotufo
- Centre for Clinical and Epidemiological Research, University of São Paulo, São Paulo, Brazil
| | - Alireza Esteghamati
- Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Graeme J Hankey
- School of Medicine and Pharmacology, University of Western Australia, School of Medicine and Pharmacology, Perth, Australia
| | - Raghib Ali
- Nuffield Department of Population Health, University of Oxford, Oxford, England
| | - Raimundas Lunevicius
- Department of Neuropsychopharmacology, Aintree University Hospital NHS Foundation Trust, Liverpool, England
| | - Reza Malekzadeh
- Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Robert Dellavalle
- Veterans Affairs Eastern Colorado Health Care System, Denver61Department of Dermatology, University of Colorado School of Medicine, Denver
| | - Robert Weintraub
- University of Melbourne, Melbourne, Australia63Royal Children's Hospital, Melbourne, Australia
| | - Robyn Lucas
- National Centre for Epidemiology and Population Health, Research School of Population Health, The Australian National University, Canberra, Australia
| | - Roderick Hay
- International Foundation for Dermatology, London, England
| | - David Rojas-Rueda
- Centre of Research in Environmental Epidemiology (CREAL), Barcelona, Spain
| | | | - Sadaf G Sepanlou
- Digestive Diseases Research Institute, Shariati Hospital, Tehran, Iran
| | - Sandra Nolte
- Charité University Medicine Berlin, Berlin, Germany
| | - Scott Patten
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | | | | | | | - Ivy Shiue
- Northumbria University, Newcastle upon Tyne, England75University of Edinburgh, Edinburgh, Scotland
| | - Tim Driscoll
- Sydney School of Public Health, University of Sydney, Sydney, Australia
| | - Tommi Vasankari
- UKK Institute for Health Promotion Research, Tampere, Finland
| | | | - Vafa Rahimi-Movaghar
- Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Vasiliy V Vlassov
- National Research University Higher School of Economics, Moscow, Russia
| | - W S Marcenes
- Barts and The London School of Medicine and Dentistry, University of London, London, England
| | | | - Yohannes Adama Melaku
- College of Health Sciences, School of Public Health, Mekelle University, Mekelle, Ethiopia
| | - Yuichiro Yano
- Department of Preventive Medicine, Northwestern University, Chicago, Illinois
| | | | | | - Jennifer MacLachlan
- Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, WHO Collaborating Centre for Viral Hepatitis, Melbourne, Australia
| | | | - Daniel Kim
- Department of Health Sciences, Northeastern University, Boston, Massachusetts
| | - Matias Trillini
- Mario Negri Institute for pharmacological Research, Ranica, Italy
| | - Babak Eshrati
- Arak University of Medical Sciences and Health Affairs, Arak, Iran
| | | | | | - Rakhi Dandona
- Public Health Foundation of India, National Capital Region, India
| | - Kinnari Murthy
- Public Health Foundation of India, National Capital Region, India
| | - Benjamin Cowie
- Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, WHO Collaborating Centre for Viral Hepatitis, Melbourne, Australia
| | - Azmeraw T Amare
- Department of Epidemiology, University of Groningen, Groningen, the Netherlands
| | | | | | - Coen H van Gool
- National Institute for Public Health and the Environment, Bilthoven, the Netherlands
| | - Francesco Violante
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - In-Hwan Oh
- Kyung Hee University, Seoul, South Korea
| | - Kedede Deribe
- School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia100Brighton and Sussex Medical School, Brighton, England
| | - Kjetil Soreide
- Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway102University of Bergen, Stavanger, Norway
| | - Luke Knibbs
- Department of Clinical Medicine, The University of Queensland, Brisbane, Australia
| | - Maia Kereselidze
- National Centre for Diseases Control and Public Health, Tbilisi, Georgia
| | - Mark Green
- University of Sheffield, Sheffield, England
| | | | - Nobhojit Roy
- Department of Public Health Sciences, Karolinska Institutet, Mumbai, India
| | | | | | - Yongmei Li
- Genentech Inc, San Francisco, California
| | - Hans Krueger
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - Lorenzo Monasta
- Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy
| | - Subhojit Dey
- Indian Institute of Public Health, National Capital Region, India
| | - Sara Sheikhbahaei
- Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Nima Hafezi-Nejad
- Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - G Anil Kumar
- Public Health Foundation of India, National Capital Region, India
| | | | - Lalit Dandona
- Institute for Health Metrics and Evaluation, University of Washington, Seattle93Public Health Foundation of India, National Capital Region, India
| | - Haidong Wang
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Stein Emil Vollset
- Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway113Norwegian Institute of Public Health, Bergen, Norway
| | - Ali Mokdad
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | | | - Rafael Lozano
- Institute for Health Metrics and Evaluation, University of Washington, Seattle115National Institute of Public Health, Cuernavaca, Mexico
| | - Theo Vos
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | | | - Alan Lopez
- School of Population and Global Health, University of Melbourne, Melbourne, Australia
| | - Christopher Murray
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, University of Washington, Seattle
| |
Collapse
|
189
|
Gupta S, Aitken JF, Bartels U, Brierley J, Dolendo M, Friedrich P, Fuentes-Alabi S, Garrido CP, Gatta G, Gospodarowicz M, Gross T, Howard SC, Molyneux E, Moreno F, Pole JD, Pritchard-Jones K, Ramirez O, Ries LAG, Rodriguez-Galindo C, Shin HY, Steliarova-Foucher E, Sung L, Supriyadi E, Swaminathan R, Torode J, Vora T, Kutluk T, Frazier AL. Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. Lancet Oncol 2016; 17:e163-e172. [PMID: 27300676 DOI: 10.1016/s1470-2045(15)00539-2] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 11/03/2015] [Accepted: 11/16/2015] [Indexed: 11/16/2022]
Abstract
Population-based cancer registries generate estimates of incidence and survival that are essential for cancer surveillance, research, and control strategies. Although data on cancer stage allow meaningful assessments of changes in cancer incidence and outcomes, stage is not recorded by most population-based cancer registries. The main method of staging adult cancers is the TNM classification. The criteria for staging paediatric cancers, however, vary by diagnosis, have evolved over time, and sometimes vary by cooperative trial group. Consistency in the collection of staging data has therefore been challenging for population-based cancer registries. We assembled key experts and stakeholders (oncologists, cancer registrars, epidemiologists) and used a modified Delphi approach to establish principles for paediatric cancer stage collection. In this Review, we make recommendations on which staging systems should be adopted by population-based cancer registries for the major childhood cancers, including adaptations for low-income countries. Wide adoption of these guidelines in registries will ease international comparative incidence and outcome studies.
Collapse
Affiliation(s)
- Sumit Gupta
- Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada; Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
| | - Joanne F Aitken
- Cancer Council Queensland, Fortitude Valley, Brisbane, QLD, Australia
| | - Ute Bartels
- Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada; Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - James Brierley
- Department of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada
| | - Mae Dolendo
- Southern Philippines Medical Center, Bajada, Davao City, Philippines
| | - Paola Friedrich
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
| | | | | | - Gemma Gatta
- Evaluative Epidemiology Unit, Fondazione IRCSS Instituto Nazionale dei Tumori, Milan, Italy
| | - Mary Gospodarowicz
- Department of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada
| | - Thomas Gross
- Center for Global Health, National Cancer Institute, Bethesda, MD, USA
| | | | | | - Florencia Moreno
- Argentinian Oncopediatric Registry (ROHA), National Cancer Institute, Buenos Aires, Argentina
| | - Jason D Pole
- Pediatric Oncology Group of Ontario, Toronto, ON, Canada
| | | | - Oscar Ramirez
- Registro Poblacional de Cancer de Cali, Universidad del Valle, Oficina, Cali, Valle, Colombia
| | - Lynn A G Ries
- SEER Program, National Cancer Institute, Bethesda, MD, USA
| | | | - Hee Young Shin
- Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - Eva Steliarova-Foucher
- Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - Lillian Sung
- Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada; Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Eddy Supriyadi
- Pediatric Hematology Oncology Division, Department of Pediatrics, Dr Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia
| | | | - Julie Torode
- Union for International Cancer Control, Geneva, Switzerland
| | - Tushar Vora
- Tata Memorial Hospital, Parel, Mumbai, India
| | - Tezer Kutluk
- Union for International Cancer Control, Geneva, Switzerland
| | - A Lindsay Frazier
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
| |
Collapse
|
190
|
Soeberg MJ, Luong MA, Tran VT, Tran AT, Nguyen TTH, Bui D, Nguyen THN, Takahashi K, van Zandwijk N. Estimating the incidence of malignant mesothelioma in Vietnam: a pilot descriptive cancer registration study. INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH 2016; 22:167-72. [PMID: 27388204 PMCID: PMC4984963 DOI: 10.1080/10773525.2016.1151604] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Global asbestos consumption has shifted toward lower income countries, particularly in the Asian region including Vietnam where asbestos and asbestos-containing products have been imported since the late 1960s. METHODS This pilot descriptive epidemiological study aimed to provide contemporary estimates of malignant mesothelioma incidence (histological subtype M9050/3; ICD-O-3) by gender and age group as recorded across nine cancer registries in Vietnam. RESULTS We identified 148 incident cases of malignant mesothelioma during 1987-2013. The majority of cases were recorded in the Hanoi region (n = 93) and were aged 55 years or older (n = 96). DISCUSSION By carefully reviewing existing cancer registry records in Vietnam, we identified a larger number of malignant mesothelioma cases than previously estimated. We recommend the use of cancer registry data in tracking future asbestos-related disease in Vietnam.
Collapse
Affiliation(s)
- Matthew J. Soeberg
- Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW, Australia
- Health Environment Management Agency, Hanoi, Vietnam
| | - Mai Anh Luong
- Health Environment Management Agency, Hanoi, Vietnam
| | - Van Thuan Tran
- National Institute for Cancer Control, Hanoi Vietnam
- National Cancer Hospital, Hanoi, Vietnam
| | | | | | - Dieu Bui
- National Cancer Hospital, Hanoi, Vietnam
| | | | - Ken Takahashi
- University of Occupational and Environmental Health, Fukuoka, Japan
| | - Nico van Zandwijk
- Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
191
|
Abu Hassan MR, Ismail I, Mohd Suan MA, Ahmad F, Wan Khazim WK, Othman Z, Mat Said R, Tan WL, Mohammed SRNS, Soelar SA, Nik Mustapha NR. Incidence and mortality rates of colorectal cancer in Malaysia. Epidemiol Health 2016; 38:e2016007. [PMID: 26971697 PMCID: PMC5081307 DOI: 10.4178/epih.e2016007] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 03/09/2016] [Indexed: 12/16/2022] Open
Abstract
OBJECTIVES This is the first study that estimates the incidence and mortality rate for colorectal cancer (CRC) patients in Malaysia by sex and ethnicity. METHODS The 4,501 patients were selected from National Cancer Patient Registry-Colorectal Cancer data. Patient survival status was cross-checked with the National Registration Department. The age-standardised rate (ASR) was calculated as the proportion of CRC cases (incidence) and deaths (mortality) from 2008 to 2013, weighted by the age structure of the population, as determined by the Department of Statistics Malaysia and the World Health Organization world standard population distribution. RESULTS The overall incidence rate for CRC was 21.32 cases per 100,000. Those of Chinese ethnicity had the highest CRC incidence (27.35), followed by the Malay (18.95), and Indian (17.55) ethnicities. The ASR incidence rate of CRC was 1.33 times higher among males than females (24.16 and 18.14 per 100,000, respectively). The 2011 (44.7%) CRC deaths were recorded. The overall ASR of mortality was 9.79 cases, with 11.85 among the Chinese, followed by 9.56 among the Malays and 7.08 among the Indians. The ASR of mortality was 1.42 times higher among males (11.46) than females (8.05). CONCLUSIONS CRC incidence and mortality is higher in males than females. Individuals of Chinese ethnicity have the highest incidence of CRC, followed by the Malay and Indian ethnicities. The same trends were observed for the age-standardised mortality rate.
Collapse
Affiliation(s)
- Muhammad Radzi Abu Hassan
- Department of Medicine, Sultanah Bahiyah Hospital, Alor Setar, Malaysia.,Clinical Research Centre, Sultanah Bahiyah Hospital, Alor Setar, Malaysia
| | - Ibtisam Ismail
- Clinical Research Centre, Sultanah Bahiyah Hospital, Alor Setar, Malaysia
| | | | - Faizah Ahmad
- Clinical Research Centre, Sultanah Bahiyah Hospital, Alor Setar, Malaysia
| | | | - Zabedah Othman
- Department of Radiotherapy and Oncology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
| | | | - Wei Leong Tan
- Clinical Research Centre, Sultanah Bahiyah Hospital, Alor Setar, Malaysia
| | | | | | | |
Collapse
|
192
|
Abstract
With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of China's massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high-quality data from an additional number of population-based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population-based cancer registries (2009-2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000-2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age-standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P = .1), whereas they increased significantly (+2.2% per year; P < .05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (-1.4% per year; P < .05) and females (-1.1% per year; P < .05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.
Collapse
Affiliation(s)
- Wanqing Chen
- Deputy Director, National Office for Cancer Prevention and Control, National Cancer Center, Beijing, China
| | - Rongshou Zheng
- Associate Researcher, National Office for Cancer Prevention and Control, National Cancer Center, Beijing, China
| | - Peter D Baade
- Senior Research Fellow, Cancer Council Queensland, Brisbane, Queensland, Australia
| | - Siwei Zhang
- Associate Professor, National Office for Cancer Prevention and Control, National Cancer Center, Beijing, China
| | - Hongmei Zeng
- Associate Professor, National Office for Cancer Prevention and Control, National Cancer Center, Beijing, China
| | - Freddie Bray
- Head, Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - Ahmedin Jemal
- Vice President, Surveillance and Health Services Research Program, American Cancer Society, Atlanta, GA
| | - Xue Qin Yu
- Research Fellow, Cancer Council New South Wales, Sydney, New South Wales, Australia
- Adjunct Lecturer, Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia
| | - Jie He
- Director, National Cancer Center, Beijing, China
| |
Collapse
|
193
|
Monshi B, Vujic M, Kivaranovic D, Sesti A, Oberaigner W, Vujic I, Ortiz-Urda S, Posch C, Feichtinger H, Hackl M, Rappersberger K. The burden of malignant melanoma – Lessons to be learned from Austria. Eur J Cancer 2016; 56:45-53. [DOI: 10.1016/j.ejca.2015.11.026] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Revised: 11/29/2015] [Accepted: 11/30/2015] [Indexed: 11/30/2022]
|
194
|
Pearce EN, Lee SL, Weiss R, Magner J, Garber JR, Campion FX, Leung AM. Unique obstacles to establishing thyroid cancer registries. J Clin Transl Endocrinol 2016; 3:12-13. [PMID: 29159122 PMCID: PMC5680439 DOI: 10.1016/j.jcte.2015.12.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Elizabeth N Pearce
- Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston, MA, USA
| | - Stephanie L Lee
- Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston, MA, USA
| | - Richard Weiss
- Medical Affairs, Genzyme Corporation, a Sanofi company, Cambridge, MA, USA
| | - James Magner
- Medical Affairs, Genzyme Corporation, a Sanofi company, Cambridge, MA, USA
| | - Jeffrey R Garber
- Endocrine Division, Harvard Vanguard Medical Associates, Boston, MA, USA
| | - F X Campion
- Department of Population Medicine, Harvard Medical School, Boston, MA, USA
| | - Angela M Leung
- Division of Endocrinology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
| |
Collapse
|
195
|
Holleczek B, Brenner H. Implications from Under-reporting at Lifetime, Death Certificate Notifications and Trace-back on the Recorded Incidence of a "Newly" Established Population-based Cancer Registry. Methods Inf Med 2015; 55:182-92. [PMID: 26678331 DOI: 10.3414/me15-01-0004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Accepted: 10/22/2015] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Population-based cancer registries (CRs) are powerful tools for measuring cancer burden and progress against cancer. The study's objective was to investigate the effects of under-reporting at lifetime, death certificate notifications, and trace-back on the incidence a newly established population-based CR may record during its initial 15 years of operation. METHODS Using cancer data of nine CRs of the SEER programme we performed model calculations to investigate temporal trends of the recorded incidence that might be expected if registration started in 1995 with gradually increasing proportions of cancers reported to the CR. It was assumed that the CR obtains all death certificates providing cancer as the underlying cause of death. Different scenarios with regard to the development of the proportions of cancers reported to the CR and the use of trace-back were evaluated. RESULTS Our model calculations demonstrated that the inclusion of cancers notified from death certificates which were diagnosed prior to the start of registration and which attribute to the incidence estimates of the year of death ('prevalent' cases) may compensate under-reporting typically observed right after the start of a CR. The recorded incidence may even be overestimated during the first years of registration, if large amounts of prevalent cancers are notified from death certificates (e.g. overestimation of lung cancer incidence by 8% and 21% in the first year of registration, if the proportions of cases reported were 50% and 70% in that year, overestimation of myeloma incidence still exceeding 5% after eight years of registration, if the proportion of cases reported to the CR had reached 97.5% after six years). Trace-back may effectively reduce the recorded surplus cancer cases. CONCLUSIONS During the initial years of registration, the inclusion of prevalent cancers from death certificates may compensate the higher amount of underreporting right after the start of a CR. Accurate incidence estimates may nevertheless be observed for highly fatal cancers if substantial proportions of cancer cases are missed at lifetime, however apparent incidence trends observed in the initial years of registration need to be interpreted with caution.
Collapse
Affiliation(s)
- B Holleczek
- Dr. sc. hum. Bernd Holleczek, Saarland Cancer Registry, Präsident Baltz Straße 5, 66119 Saarbrücken, Germany, E-mail:
| | | |
Collapse
|
196
|
Khodadost M, Yavari P, Babaei M, Mosavi-Jarrahi A, Sarvi F, Mansori K, Khodadost B. Estimating the completeness of gastric cancer registration in Ardabil/Iran by a capture-recapture method using population-based cancer registry data. Asian Pac J Cancer Prev 2015; 16:1981-6. [PMID: 25773798 DOI: 10.7314/apjcp.2015.16.5.1981] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Knowledge of cancer incidences is essential for cancer prevention and control programs. Capture-recapture methods have been recommended for reducing bias and increasing the accuracy of cancer incidence estimations. This study aimed to estimate the completeness of gastric cancer registration by the capture-recapture method based on Ardabil population-based cancer registry data. MATERIALS AND METHODS All new cases of gastric cancer reported by three sources, pathology reports, death certificates and medical records that reported to Ardabil population-based cancer registry in 2006 and 2008 were enrolled in the study. The duplicate cases based on the similarity of first name, surname and fathers names were identified between sources. The estimated number of gastric cancers was calculated by the log-linear method using Stata 12 software. RESULTS A total of 857 new cases of gastric cancer were reported from three sources. After removing duplicates, the reported incidence rates for the years 2006 and 2008 were 35.3 and 32.5 per 100,000 population, respectively. The estimated completeness calculated by log-linear method for these years was 36.7 and 36.0, respectively. CONCLUSIONS These results indicate that none of the sources of pathology reports, death certificates and medical records individually or collectively fully cover the incident cases of gastric cancer. We can obtain more accurate estimates of incidence rates using the capture-recapture method.
Collapse
Affiliation(s)
- Mahmoud Khodadost
- Department of Epidemiology, Faculty of Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran E-mail : p.yavari-grc.sbmu.ac.ir
| | | | | | | | | | | | | |
Collapse
|
197
|
Smith BL, Ramadan M, Corley B, Hablas A, Seifeldein IA, Soliman AS. Measuring the effect of improvement in methodological techniques on data collection in the Gharbiah population-based cancer registry in Egypt: Implications for other Low- and Middle-Income Countries. Cancer Epidemiol 2015; 39:1010-4. [PMID: 26590335 DOI: 10.1016/j.canep.2015.11.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Revised: 09/24/2015] [Accepted: 11/01/2015] [Indexed: 11/28/2022]
Abstract
The purpose of this study was to describe and quantify procedures and methods that maximized the efficiency of the Gharbiah Cancer Registry (GPCR), the only population-based cancer registry in Egypt. The procedures and measures included a locally-developed software program to translate names from Arabic to English, a new national ID number for demographic and occupational information, and linkage of cancer cases to new electronic mortality records of the Ministry of Health. Data was compiled from the 34,058 cases from the registry for the years 1999-2007. Cases and registry variables about demographic and clinical information were reviewed by year to assess trends associated with each new method or procedure during the study period. The introduction of the name translation software in conjunction with other demographic variables increased the identification of detected duplicates from 23.4% to 78.1%. Use of the national ID increased the proportion of cases with occupation information from 27% to 89%. Records with complete mortality information increased from 18% to 43%. Proportion of cases that came from death certificate only, decreased from 9.8% to 4.7%. Overall, the study revealed that introducing and utilizing local and culture-specific methodological changes, software, and electronic non-cancer databases had a significant impact on data quality and completeness. This study may have translational implications for improving the quality of cancer registries in LMICs considering the emerging advances in electronic databases and utilization of health software and computerization of data.
Collapse
Affiliation(s)
- Brittney L Smith
- Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198-4395, U.S.A
| | | | - Brittany Corley
- Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198-4395, U.S.A
| | | | | | - Amr S Soliman
- Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198-4395, U.S.A.
| |
Collapse
|
198
|
β-Elemene inhibits the proliferation of esophageal squamous cell carcinoma by regulating long noncoding RNA-mediated inhibition of hTERT expression. Anticancer Drugs 2015; 26:531-9. [PMID: 25646744 DOI: 10.1097/cad.0000000000000216] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The study aimed to clarify the relationship between β-elemene, a long noncoding RNA (lncRNA), and human telomerase reverse transcriptase (hTERT) in esophageal carcinoma ECA-109 cells. The proliferation of ECA-109 cells was measured using a CCK-8 kit and flow cytometry. PCR microarray and real-time RT-PCR were designed to determine lncRNA expression in ECA-109 cells before and after treatment with β-elemene. Western blot was used to detect the hTERT level after the differentially expressed lncRNAs in ECA-109 cells were interfered with small interfering RNA (siRNA). On treatment with β-elemene, the proliferation of ECA-109 cells was notably inhibited, and about 85% of the lncRNAs showed higher expression levels in ECA-109 cells than in those untreated cells, from which, CDKN2B-AS1 was screened out. A specific siRNA (si-CDKN2B-AS1) that targets the β-elemene-mediated lncRNA CDKN2B-AS1 was designed, synthesized, and applied to treat ECA-109 cells. Its interference efficiency reached as high as 89.6%. When ECA-109 cells were transfected with the siRNA, the hTERT level was increased by 84.7%. The CCK-8 assay showed that the proliferation of ECA-109 cells treated with β-elemene was significantly promoted after siRNA transfection (P<0.01). It was also shown by flow cytometry that, compared with the scramble-treated group (negative control), the proliferation index value of ECA-109 cells in the si-CDKN2B-AS1 treatment group was notably increased (25.7 vs. 51.7%) and the TERT protein level was increased by 67.25% after the cells were treated with si-CDKN2B-AS1. The chemotherapeutic drug β-elemene suppressed the proliferation of esophageal carcinoma ECA-109 cells by regulating the inhibition of hTERT expression by lncRNA CDKN2B-AS1.
Collapse
|
199
|
Cao SM, Xu YJ, Lin GZ, Huang QH, Wei KR, Xie SH, Liu Q. Estimation of cancer burden in Guangdong Province, China in 2009. CHINESE JOURNAL OF CANCER 2015; 34:594-601. [PMID: 26573607 PMCID: PMC4647496 DOI: 10.1186/s40880-015-0060-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 10/19/2015] [Indexed: 01/28/2023]
Abstract
Background Surveying regional cancer incidence and mortality provides significant data that can assist in making health policy for local areas; however, the province- and region-based cancer burden in China is seldom reported. In this study, we estimated cancer incidence and mortality in Guangdong Province, China and presented basic information for making policies related to health resource allocation and disease control. Methods A log-linear model was used to calculate the sex-, age-, and registry-specific ratios of incidence to mortality (I/M) based on cancer registry data from Guangzhou, Zhongshan, and Sihui between 2004 and 2008. The cancer incidences in 2009 were then estimated according to representative I/M ratios and the mortality records from eight death surveillance sites in Guangdong Province. The cancer incidences in each city were estimated by the corresponding sex- and age-specific incidences from cancer registries or death surveillance sites in each area. Finally, the total and region-based cancer incidences and mortalities for the entire population of Guangdong Province were summarized. Results The estimated I/M ratios in Guangzhou (3.658), Zhongshan (2.153), and Sihui (1.527) were significantly different (P < 0.001), with an average I/M ratio of 2.446. Significant differences in the estimated I/M ratios were observed between distinct age groups and the three cancer registries. The estimated I/M ratio in females was significantly higher than that in males (2.864 vs. 2.027, P < 0.001). It was estimated that there were 163,376 new cancer cases (99,689 males and 63,687 females) in 2009; it was further estimated that 115,049 people (75,054 males and 39,995 females) died from cancer in Guangdong Province in 2009. The estimated crude and age-standardized rate of incidences (ASRI) in Guangdong Province were 231.34 and 246.87 per 100,000 males, respectively, and 156.98 and 163.57 per 100,000 females, respectively. The estimated crude and age-standardized rate of mortalities (ASRM) in Guangdong Province were 174.17 and 187.46 per 100,000 males, respectively, and 98.59 and 102.00 per 100,000 females, respectively. In comparison with the western area and the northern mountain area, higher ASRI and ASRM were recorded in the Pearl River Delta area and the eastern area in both males and females. Conclusions Cancer imposes a heavy disease burden, and cancer patterns are unevenly distributed throughout Guangdong Province. More health resources should be allocated to cancer control, especially in the western and northern mountain areas.
Collapse
Affiliation(s)
- Su-Mei Cao
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Cancer Prevention, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Yan-Jun Xu
- Institute of Control and Prevention for Chronic Non-infective Disease, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, 511430, Guangdong, P.R. China.
| | - Guo-Zhen Lin
- Department of Disease Surveillance, Guangzhou Center for Disease Control and Prevention, Guangzhou, 510440, Guangdong, P.R. China.
| | - Qi-Hong Huang
- Sihui Institute of Cancer, Sihui, 530000, Guangdong, P.R. China.
| | - Kuang-Rong Wei
- Institute of Cancer, Zhongshan People's Hospital, Zhongshan, 528403, Guangdong, P.R. China.
| | - Shang-Hang Xie
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Cancer Prevention, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| | - Qing Liu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China. .,Department of Cancer Prevention, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P.R. China.
| |
Collapse
|
200
|
Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Antoni S, Soerjomataram I, Forman D. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer 2015; 137:2060-71. [PMID: 26135522 DOI: 10.1002/ijc.29670] [Citation(s) in RCA: 263] [Impact Index Per Article: 29.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Accepted: 06/24/2015] [Indexed: 11/10/2022]
Abstract
Cancer Incidence in Five Continents (CI5), a longstanding collaboration between the International Agency for Research on Cancer and the International Association of Cancer Registries, serves as a unique source of cancer incidence data from high-quality population-based cancer registries around the world. The recent publication of Volume X comprises cancer incidence data from 290 registries covering 424 populations in 68 countries for the registration period 2003-2007. In this article, we assess the status of population-based cancer registries worldwide, describe the techniques used in CI5 to evaluate their quality and highlight the notable variation in the incidence rates of selected cancers contained within Volume X of CI5. We also discuss the Global Initiative for Cancer Registry Development as an international partnership that aims to reduce the disparities in availability of cancer incidence data for cancer control action, particularly in economically transitioning countries, already experiencing a rapid rise in the number of cancer patients annually.
Collapse
Affiliation(s)
- F Bray
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| | - J Ferlay
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| | - M Laversanne
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| | - D H Brewster
- Scottish Cancer Registry, NHS National Services Scotland, Edinburgh, United Kingdom
| | | | - B Kohler
- North American Association of Central Cancer Registries, USA
| | - M Piñeros
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
- Instituto Nacional de Cancerología, Colombia
| | - E Steliarova-Foucher
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| | | | - S Antoni
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| | - I Soerjomataram
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| | - D Forman
- Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|